Primer: ABLBio (298380 KS) - Aug 2026
ABLBio is a clinical-stage biotechnology company specializing in bispecific antibody technology for treating immuno-oncology and...
107 Views
ABLBio (298380 KS): Pipeline Is Progressing Toward Commercialization
​ABLBio's ADC candidate ABL111 enters global Phase 2 trial for gastric cancer, with $12B opportunity by 2030. FDA also approves Phase 1 trial for...
254 Views
ABLBio (298380 KS): Funding From Lilly To Strengthen Drug Development Capabilities
ABLBio secured equity investment of KRW22B from Eli Lilly. ABL Bio plans to use the proceeds to advance its core technologies, including bispecific...
384 Views
ABL Bio: Equity Investment of 22 Billion Won from Eli Lilly
On 14 November, ABLBio (298380 KS) announced that it has signed an equity investment agreement with Eli Lilly & Co (LLY US) worth 22 billion won...
2.5k Views
APAC Healthcare Weekly (May 3) – Simcere, Beigene, Otsuka, Kyowa Kirin, Sun Pharma
NMPA accepted Simcere’s resubmitted NDA for Rademikibart. Beigene got FDA’s priority review for label expansion of Tevimra. Sun Pharma is acquiring...
299 Views